Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The purpose of this study was to analyze the prevention and control effects of the three-phase global tuberculosis control strategy, and analyze the influencing factors.
Methods: We collected age-standardized incidence, prevalence, and mortality (ASIR, ASPR, and ASDR) data from the Global Burden of Disease Study (GBD 2021) database. Annual percentage change (AAPC) of ASIR, ASPR and ASDR were analyzed by Joinpoint regression. Correlation and decomposition analyses explored related epidemiological factors.
Results: At the global level, in the first phase Directly-Observed Treatment Strategy (DOTS), the annual reduction in incidence was 1.18%, and prevalence was 0.71%. In the second phase Stop TB, the cumulative mortality decrease was 56.44% which met the desired goal. However, the cumulative decrease of prevalence was only 20.45%. In the third phase End TB, annual rate of reduction in mortality was 3.33%, while the annual rate of reduction in incidence was 1.14%. ASPR showed a large decrease in both low socio-demographic index (SDI) and high SDI regions, the decrease in medium SDI region was small, which might be dominated by demographic factors at the DOTS stage, changed to epidemiologic in the Stop TB stage and to aging factors in the End TB stage.
Conclusion: The control of TB morbidity and mortality had a great achievement in all the 3 different phases of the TB control strategy, and a concerted global effort is still needed in phase 3 to reach the END TB goal. TB prevalence control needs to be emphasized, especially in the middle and high SDI areas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arbres.2024.11.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of Targeted Next Generation Sequencing for TB drug-resistance testing as an alternative to the standard of care in South Africa.
Clin Infect Dis
September 2025
Department of Global Health, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Background: South Africa faces emerging resistance to TB drugs like bedaquiline. Phenotypic drug susceptibility testing (DST), the current reference standard for bedaquiline DST, has long turnaround times. Targeted next-generation sequencing (tNGS) offers a comprehensive alternative, potentially delivering faster results.
View Article and Find Full Text PDFUltra-high field strength electroporation enables efficient DNA transformation and genome editing in nontuberculous mycobacteria.
Microbiol Spectr
September 2025
Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Efficient DNA delivery is essential for genetic manipulation of mycobacteria and for dissecting their physiology, pathogenesis, and drug resistance. Although electroporation enables transformation efficiencies exceeding 10⁵ CFU per µg DNA in and , it remains highly inefficient in many nontuberculous mycobacteria (NTM), including . Here, we discovered that NTM such as exhibit exceptional tolerance to ultra-high electric field strengths and that hypertonic preconditioning partially protects cells from electroporation-induced damage.
View Article and Find Full Text PDF"Engineering Rifampicin-Encapsulated Inhalable Microparticles for Precision Tuberculosis Therapy: In Vivo Distribution and Therapeutic Evaluation".
J Drug Target
September 2025
Department of Pharmaceutics, ShriRam College of Pharmacy, Banmore, Morena-476444, Madhya Pradesh, India.
Tuberculosis (TB) continues to cause significant global mortality, highlighting the need for improved drug delivery systems. The objective of this paper focuses in describing the formulation, optimization and in vivo assessment of rifampicin encapsulated PLGA microparticles for site-specific inhalation therapy. Microparticles for inhalation were produced by spray drying, and the DoE methodology was applied to reach the most suitable aerodynamic properties (mass median aerodynamics diameter (MMAD) 2.
View Article and Find Full Text PDFEvaluation of Late Postoperative Pulmonary Function Following Lobectomy in Patients With Tubercular and Non-tubercular Lung Diseases.
Cureus
August 2025
Thoracic Surgery, National Institute of Diseases of the Chest and Hospital, Dhaka, BGD.
Background: Pulmonary function testing, especially spirometry, is essential for assessing patients after pulmonary resection for tubercular and non-tubercular diseases. Tuberculosis (TB) remains a major cause of death globally, while other non-tubercular conditions such as lung abscess, bullous disease, and bronchiectasis also require lobectomy. This study aimed to compare late postoperative pulmonary function following lobectomy between TB and non-TB patients.
View Article and Find Full Text PDFPhase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.
Contemp Clin Trials
September 2025
Weill Cornell Medicine Center for Global Health, New York, NY, USA.
Introduction: Preclinical and clinical study data show that combining bedaquiline (B or BDQ), moxifloxacin (M), and pyrazinamide (Z), known as BMZ, has potent antimicrobial activity that might shorten treatment duration for drug-susceptible pulmonary tuberculosis.
Methods/design: We describe the design of Tuberculosis Trials Consortium (TBTC) Study 38/CRUSH-TB (NCT05766267), an open-label multicenter international randomized controlled phase 2C trial that compares two four-month regimens, BMZ plus rifabutin (Rb) (2BMZRb/2BMRb) or BMZ plus delamanid (D or DLM) (2BMZD/2BMD), with standard 6-months isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). All drugs are administered seven days per week, under direct observation, at least five days per week.